Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present CSL Ltd. (OTC: CSLLY).

Full DD Report for CSLLY

Recent News from (OTC: CSLLY)

Forbes Magazine Names CSL Limited Among Top 50 Employers in the World
KING OF PRUSSIA, Pa. , March 20, 2018 /PRNewswire/ -- Forbes has named global biotechnology leader CSL Limited among the world's Top 50 employers, landing at no. 42 in the business media's annual Global 2000 survey. The Forbes list was compiled by Statista, which surveyed ...
Source: PR Newswire
Date: March, 20 2018 09:00
FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
KING OF PRUSSIA, Pa. , March 16, 2018 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra ®  (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only subcutaneous immun...
Source: PR Newswire
Date: March, 16 2018 08:00
CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
KING OF PRUSSIA, Pa. , March 15, 2018 /PRNewswire/ -- Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body, including the abdomen, face and larynx. This is what it's like for patients with hereditary angio...
Source: PR Newswire
Date: March, 15 2018 09:00
CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines
BARCELONA, Spain , March 13, 2018 /PRNewswire/ -- In a keynote address on patients' access to medicines at the eyeforpharma Barcelona summit,  CSL Chief Executive Officer and Managing Director Paul Perreault told fellow biotech industry leaders that access to life-s...
Source: PR Newswire
Date: March, 13 2018 12:19
Seqirus answers the call for better and faster influenza vaccine technologies
SUMMIT, N.J. , March 13, 2018 /PRNewswire/ -- Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today welcomed calls from US Health Officials for greater efforts to be made to develop better and faster influenza vaccine technologies.  The comments were ...
Source: PR Newswire
Date: March, 13 2018 11:43
ADMA Biologics: Almost Ready To Run Between The Toes Of Giants
1. Introduction to the Investment Thesis ADMA Biologics is a sub-$100m capitalization healthcare company that is based in Boca Raton, Florida. The company is aiming to commercialize a novel high-titer hyper-immune globulin product for the treatment of RSV and related respiratory viruses...
Source: SeekingAlpha
Date: March, 06 2018 07:36
CSL: Australia's Best Growth Business?
Australia is home to a few select high-quality gross businesses, and CSL Ltd. ( OTCPK:CSLLY ) may be amongst the top of the bunch. CSL is a plasma fractioning business that was privatized by the Australian government in the mid-1990s. Over the last 15 years, CSL has been an exceptional per...
Source: SeekingAlpha
Date: March, 05 2018 11:34
CSL Ltd. ADR 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by CSL Ltd. ADR in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: February, 14 2018 13:48
CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
MELBOURNE, Australia and VANCOUVER , British Columbia , Dec. 5, 2017 /PRNewswire/ -- CSL Limited (ASX:CSL; USOTC:CSLLY) and Vitaeris Inc. (Vitaeris) today announced that they have entered into a strategic collaboration and purchase option agreement to expedite the development of...
Source: PR Newswire
Date: December, 05 2017 08:39
CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy
KING OF PRUSSIA, Pa. , Dec. 4, 2017 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that it will proceed with a global Phase 3 cardiovascular morbidity and mortality trial for CSL112, the company's novel apolipoprotein A-I (apoA-I) infusion therapy. The study, Ap...
Source: PR Newswire
Date: December, 04 2017 16:25


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About CSL Ltd. (OTC: CSLLY)

Logo for CSL Ltd. (OTC: CSLLY)

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent serious and rare medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself. Innovation is at the heart of everything we do. It is reflected in our creation of state of the art plasma collection and manufacturing facilities, our investment in improving current therapies, finding new indications for existing therapies, and innovating new therapeutic products for unmet needs


Contact Information



Current Management

  • Paul Perreault / CEO, Managing Director
  • Paul Perreault / President, CEO
  • Mark Dehring / Director, Inv. Rel.
  • John Shine / Chairman

Current Share Structure

  • Market Cap: $3,080,522,556 - 03/09/2018
  • Authorized: 500,000,000 - 09/01/2015
  • Issue and Outstanding: 23,725,528 - 09/01/2015


Daily Technical Chart for (OTC: CSLLY)

Daily Technical Chart for (OTC: CSLLY)

Stay tuned for daily updates and more on (OTC: CSLLY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CSLLY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CSLLY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CSLLY and does not buy, sell, or trade any shares of CSLLY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: